Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13-15, 2016

Cancer Immunol Immunother. 2018 Jun;67(6):1023-1030. doi: 10.1007/s00262-017-2078-8. Epub 2017 Oct 20.

Vincenzo Russo^{1

2}, Carla Chiarucci³, Maria Fortunata Lofiego^{3

4}, Carolina Fazio³, Erica Bertocci³, Ornella Cutaia³, Gianluca Giacobini^{3

4}, Andrea Lazzeri³, Antonello Lamboglia³, Maresa Altomonte³, Patrizia Tunici³, Alessia Covre³, Michele Maio^{5

6}

¹ Cancer Gene Therapy Unit, Division of Molecular Oncology, Scientific Institute S. Raffaele, Milan, Italy.
² Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy.
³ Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, V.le Bracci, 16, Siena, Italy.
⁴ University of Siena, Siena, Italy.
⁵ Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy. mmaiocro@gmail.com.
⁶ Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, V.le Bracci, 16, Siena, Italy. mmaiocro@gmail.com.

No abstract available

Keywords: Cancer vaccines; Checkpoint blockade agents; Immunotherapy; NIBIT; Targeted therapies.